Af­ter get­ting skunked by ri­vals, Pfiz­er touts ‘break­through’ can­cer drug lor­la­tinib, heads to the FDA

Pfiz­er’s Xalko­ri has be­come a Phase III punch­ing bag of sorts for top ri­vals in the can­cer field. In June No­var­tis’ Zyka­dia picked up an FDA ap­proval to chal­lenge Xalko­ri in front­line ALK-pos­i­tive lung can­cer. And Roche’s Ale­cen­sa has been whup­ping up on Xalko­ri as well, prov­ing bet­ter at cut­ting the risk of dis­ease pro­gres­sion.

So it’s no won­der that Pfiz­er is tak­ing its pos­i­tive Phase II da­ta — post­ed to­day — for its next-gen suc­ces­sor lor­la­tinib straight to reg­u­la­tors.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.